Wellbutrin SR Patent Needs Further Review, Appeals Court Agrees With GSK
Executive Summary
An appeals court ruling for GlaxoSmithKline in Wellbutrin SR patent litigation against Andrx finds the district court erred in its construction of GSK's patent claims
You may also be interested in...
Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA
Impax' bupropion sustained-release generic is cleared for launch following an appeals court ruling that the company does not infringe GlaxoSmithKline's Wellbutrin SR/Zyban patent
Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA
Impax' bupropion sustained-release generic is cleared for launch following an appeals court ruling that the company does not infringe GlaxoSmithKline's Wellbutrin SR/Zyban patent
Eon Wellbutrin SR Generic Launch Could Slow GSK Conversion Efforts
Eon's launch of generic bupropion extended-release (Wellbutrin SR) should allow it to grab significant market share before GlaxoSmithKline fully converts SR patients to once-daily Wellbutrin XL